Prague, Czechia

Miroslav Rybak


Average Co-Inventor Count = 7.5

ph-index = 1

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 1990-1992

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Miroslav Rybak

Introduction

Miroslav Rybak is a distinguished inventor based in Prague, Czech Republic. He has made significant contributions to the field of biomedical innovations, holding two patents that demonstrate his expertise and creativity in developing novel solutions for health-related issues.

Latest Patents

Rybak's latest patents reflect his commitment to advancing medical science. The first patent concerns concentrates of coagulation factors II, VII, IX, and X, along with a method for their preparation. This method involves selective adsorption on an equilibrated carrier and aims to provide valuable tools for detecting coagulation factor VII and assessing mammalian inflammatory diseases in laboratory settings. His second patent focuses on peptide derivatives and their preparation processes. These derivatives, under physiologic conditions, are converted into active spirocyclic peptide derivatives, functioning as pro-drugs with prolonged biological effects.

Career Highlights

Throughout his career, Rybak has worked with prominent companies such as Tessek Sdruzeni Praha and Spofa, Spojene Podniky Pro. His positions within these organizations have allowed him to deepen his expertise and contribute to important biomedical research and development initiatives.

Collaborations

In his professional journey, Miroslav Rybak has collaborated with notable colleagues including Evzen Kasafirek and Alena Roubalova. These partnerships have been instrumental in driving innovation and fostering a collaborative environment for research and development.

Conclusion

Miroslav Rybak's contributions to the field of biomedical innovations through his patents and collaborations underscore his role as a leading inventor. His work not only enhances our understanding of coagulation factors but also paves the way for new therapeutic avenues in the treatment of inflammatory diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…